Table 1 Clinical characteristics and laboratory findings of patients with RA
PBMC | SFMC | |
|---|---|---|
Total number | 9 | 6 |
Age, mean ± SD (years) | 60.8 ± 19.2 | 52.5 ± 20.3 |
Male, n (%) | 3 (33.3) | 1 (16.6) |
RF positive, n (%) | 8 (88.8) | 5 (83.3) |
Anti-CCP Ab positive, n (%) | 8 (88.8) | 5 (83.3) |
Recent medications | ||
Steroid, n (%) | 7 (77.7) | 6 (100.0) |
Steroid dose, mean ± SD | 5.4 ± 3.4 | 6.6 ± 2.7 |
Methotrexate use, n (%) | 9 (100.0) | 6 (100.0) |
Leflunomide use, n (%) | 3 (33.3) | 1 (16.6) |
Tacrolimus use, n (%) | 3 (33.3) | 2 (33.3) |
TNF-α blocker use, n (%) | 2 (22.2) | 0 (0.0) |
Jak inhibitor use, n (%) | 0 (0.0) | 0 (0.0) |